- Home
- GSHR vs BWAY Comparison
GSHR vs BWAY Comparison
Compare GSHR & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSHR
- BWAY
- Stock Information
- Founded
- GSHR 2024
- BWAY 2003
- Country
- GSHR United States
- BWAY Israel
- Employees
- GSHR N/A
- BWAY N/A
- Industry
- GSHR
- BWAY Medical/Dental Instruments
- Sector
- GSHR
- BWAY Health Care
- Exchange
- GSHR NYSE
- BWAY Nasdaq
- Market Cap
- GSHR 205.8M
- BWAY 201.1M
- IPO Year
- GSHR 2025
- BWAY 2019
- Fundamental
- Price
- GSHR $10.06
- BWAY $10.90
- Analyst Decision
- GSHR
- BWAY Strong Buy
- Analyst Count
- GSHR 0
- BWAY 2
- Target Price
- GSHR N/A
- BWAY $14.25
- AVG Volume (30 Days)
- GSHR 4.7K
- BWAY 39.5K
- Earning Date
- GSHR 01-01-0001
- BWAY 08-05-2025
- Dividend Yield
- GSHR N/A
- BWAY N/A
- EPS Growth
- GSHR N/A
- BWAY N/A
- EPS
- GSHR N/A
- BWAY 0.08
- Revenue
- GSHR N/A
- BWAY $43,457,000.00
- Revenue This Year
- GSHR N/A
- BWAY $351.53
- Revenue Next Year
- GSHR N/A
- BWAY $21.84
- P/E Ratio
- GSHR N/A
- BWAY $54.64
- Revenue Growth
- GSHR N/A
- BWAY 26.86
- 52 Week Low
- GSHR $9.97
- BWAY $5.67
- 52 Week High
- GSHR $10.25
- BWAY $12.00
- Technical
- Relative Strength Index (RSI)
- GSHR N/A
- BWAY 57.34
- Support Level
- GSHR N/A
- BWAY $10.21
- Resistance Level
- GSHR N/A
- BWAY $12.00
- Average True Range (ATR)
- GSHR 0.00
- BWAY 0.52
- MACD
- GSHR 0.00
- BWAY 0.04
- Stochastic Oscillator
- GSHR 0.00
- BWAY 44.72
About GSHR GESHER ACQUISITION CORPORATION II ORD USD0.0001 CL A
Gesher Acquisition Corp II is a blank check company.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.